Role of blood tumor markers in predicting metastasis and local recurrence after curative resection of colon cancer.
作者： Yifan Peng , Jin Gu , Zhongmin Li , Zhiwei Zhai , Lin Wang
DOI:
关键词:
摘要: Aim To investigate the prognostic value of carcinoembryonic antigen (CEA), CA199, CA724 and CA242 in peripheral blood local draining venous colon cancer patients after curative resection. Methods 92 who received resection were retrospectively analyzed. The CEA, detected blood. Results Metastasis or recurrence was found 29 (29/92, 31.5%) during follow-up period. divided into two groups: metastasis/local group (n = 29) non-metastasis/local 63). Peripheral (p-CEA, p-CA199, p-CA724 p-CA242) comparable between groups (P > 0.05). median CEA (d-CEA) metastases/local (23.7 ± 6.9 ng/ml) significantly higher than that non-metastases/local (18.1 6.3 ng/ml; P optimal cut-off d-CEA 2.76 ng/ml, with sensitivity specificity 90% 40% prediction metastasis recurrence, respectively. correlated tumor differentiation, T stage, TNM recurrence. Subgroup analysis showed that, 41 stage II cancer, 8.78 ng/mL, 87.5% 69.7% Conclusion may be a factor for patients.
参考文章(36)
Nektaria Simiantonaki, Charles James Kirkpatrick, Caren Jayasinghe, VEGF-B expression in colorectal carcinomas and its relevance for tumor progression. Histology and Histopathology. ,vol. 28, pp. 647- 653 ,(2013) , 10.14670/HH-28.647
Rebecca Siegel, Elizabeth Ward, Otis Brawley, Ahmedin Jemal, Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: A Cancer Journal for Clinicians. ,vol. 61, pp. 212- 236 ,(2011) , 10.3322/CAAC.20121
Kazuya Muguruma, Takahiro Toyokawa, Masaichi Ohira, Katsunobu Sakurai, Masatsune Shibutani, Naoshi Kubo, Hiroshi Ohtani, Kiyoshi Maeda, Hisashi Nagahara, Kosei Hirakawa, Hiroaki Tanaka, Significance of CEA and CA19-9 combination as a prognostic indicator and for recurrence monitoring in patients with stage II colorectal cancer. Anticancer Research. ,vol. 34, pp. 3753- 3758 ,(2014)
Alvaro Figueredo, Manya L. Charette, Jean Maroun, Melissa C. Brouwers, Lisa Zuraw, Adjuvant Therapy for Stage II Colon Cancer: A Systematic Review From the Cancer Care Ontario Program in Evidence-Based Care’s Gastrointestinal Cancer Disease Site Group Journal of Clinical Oncology. ,vol. 22, pp. 3395- 3407 ,(2004) , 10.1200/JCO.2004.03.087
Yoshiki Tabuchi, Hiroyuki Deguchi, Kizuku Imanishi, Yoichi Saitoh, Comparison of carcinoembryonic antigen levels between portal and peripheral blood in patients with colorectal cancer. Correlation with histopathologic variables. Cancer. ,vol. 59, pp. 1283- 1288 ,(1987) , 10.1002/1097-0142(19870401)59:7<1283::AID-CNCR2820590709>3.0.CO;2-G
Tomomi Yakabe, Yuji Nakafusa, Kenji Sumi, Atsushi Miyoshi, Yoshihiko Kitajima, Seiji Sato, Hirokazu Noshiro, Kohji Miyazaki, Clinical significance of CEA and CA19-9 in postoperative follow-up of colorectal cancer. Annals of Surgical Oncology. ,vol. 17, pp. 2349- 2356 ,(2010) , 10.1245/S10434-010-1004-5
Stephen B. Edge, Carolyn C. Compton, The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM Annals of Surgical Oncology. ,vol. 17, pp. 1471- 1474 ,(2010) , 10.1245/S10434-010-0985-4
Jaques Waisberg, Luís Contim-Neto, Maurício da Silva Lorena Oliveira, Cláudio de Oliveira Matheus, Carlos Alberto Nagashima, Fabio Schmidt Goffi, Determination of carcinoembryonic antigen levels in peripheral and draining venous blood in patients with colorectal carcinoma Arquivos De Gastroenterologia. ,vol. 41, pp. 88- 92 ,(2004) , 10.1590/S0004-28032004000200004
Shunji Morita, Takashi Nomura, Yukio Fukushima, Takashi Morimoto, Nobuaki Hiraoka, Nobuhiro Shibata, Does serum CA19-9 play a practical role in the management of patients with colorectal cancer? Diseases of The Colon & Rectum. ,vol. 47, pp. 227- 232 ,(2004) , 10.1007/S10350-003-0041-6
Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling-Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, Gernot Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Jörg Hielscher, Michael Scholz, Sebastian Müller, Hartmut Link, Norbert Niederle, Andreas Rost, Heinz-Gert Höffkes, Markus Moehler, Reinhard U Lindig, Dominik P Modest, Lisa Rossius, Thomas Kirchner, Andreas Jung, Sebastian Stintzing, FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial Lancet Oncology. ,vol. 15, pp. 1065- 1075 ,(2014) , 10.1016/S1470-2045(14)70330-4